Action IP4 INNOCAN PHARMA CORPORATION
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues InnoCan Pharma Corporation Deutsche Boerse AG

Actions

IP4

CA45783P1027

Marché Fermé - Deutsche Boerse AG
Autres places de cotation
 17:59:44 31/05/2024 		Varia. 5j. Varia. 1 janv.
0,193 EUR +1,31% Graphique intraday de InnoCan Pharma Corporation -9,81% -1,13%
27/05 InnoCan Pharma Corporation annonce ses résultats pour le premier trimestre terminé le 31 mars 2024 CI
27/05 Innocan Pharma annonce ses résultats pour le premier trimestre 2024 avec une croissance des revenus de plus de 4 fois pour atteindre 6,8 millions de dollars MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
InnoCan Pharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
Innocan Pharma Reports First Quarter 2024 Results With Revenue Growth Of Over 4X To $6.8 Million
Innocan Pharma Corporation Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
InnoCan Pharma Corporation Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
InnoCan Pharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
Innocan Pharma Corporation Announces the Signing of an Agreement with the Hebrew University
Innocan Pharma Corporation Announces Tissue Distribution Study of LPT-CBD to the Brain
InnoCan Pharma Corporation Announces Study Findings That Lpt-Cbd Maintain Its Prolonged Release in Rabbits
InnoCan Pharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Innocan Pharma Corporation Announces Promising LPT-CBD Safety Indications
InnoCan Pharma Corporation Announces Appointment of Dr. Joseph V. Pergolizzi to its Scientific Advisory Board
Innocan Pharma Corporation Announces Promising Results from Hair Care Cream Efficacy Test
Innocan Pharma Corporation Announces Clinical Study Results
InnoCan Pharma Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Innocan Pharma Announces Promising Successful Results in Efficacy Trial of Diabetic Foot Relief Treatment
Innocan Pharma Corporation Submits New Patent Applications for Advanced Pain Relief Technology
InnoCan Pharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023
InnoCan Pharma Corporation Announces Successful Treatment of Billy with Liposomal-CBD Injection in Pre-Clinical Trial
Innocan Pharma Corporation Announces the Entering into of A Wide-Scope Commercial Distribution Agreement with UAB Medexy
Innocan Pharma Corporation Reports Novel Cannabinoid Delivery Platform Patent Application
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action INNO
  4. Action IP4
  5. Actualités InnoCan Pharma Corporation
  6. Autres langues
-40% Offre à Durée Limitée : Nos abonnements vous guident vers les meilleurs investissements de demain.
PROFITEZ-EN MAINTENANT